Biopharmaceuticals - Addiction Treatment & Behavioral Health
Strategic Profile
The company is advancing AD04 toward a pivotal Phase 3 program with refined clinical strategy, regulatory alignment, and manufacturing readiness. Recent federal appropriations directive on alternative clinical trial endpoints aligns with Adial's regulatory pathway for AD04, which targets Alcohol Use Disorder using a precision medicine approach.
Cyborg Score Rationale
Recently regained Nasdaq compliance after addressing minimum bid price requirements, resolving a critical listing risk. Clinical asset in Phase 3 with regulatory clarity, but company faces severe cash constraints with minimal headcount and ongoing liquidity pressures evidenced by equity financing activities.
Top Insights
Recently regained Nasdaq compliance on Feb 23, 2026 after maintaining $1.00+ closing bid price for 10 consecutive business days
Lead drug AD04 targets heavy-drinking patients with specific genotypes and is in preparation for new Phase 3 adaptive program informed by FDA End of Phase 2 feedback
February 2026 Congressional directive on alternative clinical trial endpoints for substance use disorders may reduce pivotal trial burden and strengthens regulatory pathway for AD04
Executed 1-for-25 reverse stock split effective Feb 5, 2026 to restore Nasdaq compliance and reduce outstanding shares from ~27.8M to ~1.1M
Named Competitors
Naltrexone — Opioid antagonist FDA-approved for AUD
Acamprosate — FDA-approved maintenance therapy for AUD
Investigational AUD Programs — Competing mechanisms for addiction treatment
Recent Developments
(Feb 2026) Regained Nasdaq compliance with minimum bid price requirement after 10 consecutive business days at $1.00+
(Feb 2026) Congressional directive on alternative AUD trial endpoints signed, potentially reducing Phase 3 trial burden from two to one
(Jan 2026) Published international PCT patent application for AD04 lead drug candidate
(Dec 2025) Warrant inducement agreement with healthcare investor for ~$2.86M in gross proceeds
Open the full interactive Adial Pharmaceuticals, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.